Stanford University

Company announces appointment of Manu Varma to Board of Directors, Dr. Christopher Elliott to Scientific Advisory Board, and Sergey Grigoryants to Chief Technology Officer SYRACUSE, N.Y., May 11, 2026 /PRNewswire/ -- Aurie announced that the Aurie Reusable No-Touch Intermittent Catheter System™ has been granted marketing authorization from the U.S. Food and Drug Administration (FDA) through the Class II De Novo pathway—establishing it as the first ever reusable intermittent urinary catheter system and creating a new device classification in an industry that exclusively relied on single-use catheters for decades. The Aurie System is slated to launch into the Veterans Health Administration spinal cord injury hospitals later this year. The Aurie System includes: a 100-use no-touch intermittent catheter; a portable catheter washer-disinfector; and pre-packaged supply pods. The system delivers single-use no-touch catheter features at a fraction of the cost. Rigorous testing—from microbiology to human factors—demonstrated the reasonable assurance of safety and effectiveness for the intended use of the Aurie System+ and set the standard for all reusable catheter systems to come. Manu Varma Joins Board of Directors Manu Varma joins Aurie as an independent Board Director. He brings more than two decades of chronic care leadership, most recently as President of North America at Coloplast, where he oversaw several business lines, including its largest market for intermittent catheters. "Aurie is addressing the industry's biggest challenge by combining sustainability and user-centered design to define a new standard of care. The De Novo clearance is a major milestone, and I'm excited to work with this team as they take the business to the next level," said Manu Varma Dr. Christopher Elliott Joins Scientific Advisory Board Christopher S. Elliott, MD, PhD joins Aurie's Scientific Advisory Board. Dr. Elliott is a leading voice for sustainable alternatives to single-use catheters and a Clinical Associate Professor of Urology at Stanford University. Sergey Grigoryants Promoted to Chief Technology Officer Sergey Grigoryants has been promoted from Vice President of Engineering to Chief Technology Officer. He will oversee the company's technology roadmap, including infection-detecting sensor-enabled catheters. About Aurie Aurie is a medical device company that has developed the first safely+ reusable no-touch intermittent catheter system. Aurie has been supported by Lakehouse Ventures, among others. Learn more at livewithaurie.com. +When used in accordance with the Instructions for Use. SOURCE CathBuddy, Inc. 21% more press release views with Request a Demo

BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 40,250 shares of Class A common stock and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock to ten (10) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on May 4, 2026 has an exercise price per share equal to $35.51, Vera Therapeutics’ closing trading price on May 4, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit . For more information, please contact: Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com Media Contact: Debra Charlesworth Vera Therapeutics 415-854-8051 corporatecommunications@veratx.com

BOSTON, May 7, 2026 /PRNewswire/ -- Embr Labs, the leader in digital thermal health technology, announced three milestones that underscore its position at the forefront of wearable thermal technology. Marked by clinical validation from Stanford University, a strategic intellectual property expansion in Japan, and the launch of a revolutionary open-source research API and SDK, Embr Labs is rapidly transforming how the world harnesses temperature to improve human health. For millions navigating Postural Tachycardia Syndrome (POTS), temperature intolerance has long been underrecognized, debilitating, and undertreated. A pilot study led by Dr. Mitchell Miglis at Stanford University, recently published in Autonomic Neuroscience: Basic and Clinical, demonstrates that the Embr Wave™ wearable delivers profound relief. Over a 28-day period, POTS patients experienced statistically significant quality of life (QoL) improvements. Notably, patients reporting moderate-to-severe impact on leisure activities plummeted from 45% to 0% (p=0.04), while the negative impact on overall enjoyment of life was cut nearly in half. "Most patients with POTS report temperature intolerance, which can be quite debilitating and significantly limit their quality of life. Despite this, research studies on this topic are limited, and treatment options are often ineffective," said Dr. Miglis. "In this open-label study, we evaluated the efficacy of the Embr wave in 22 patients with POTS. We found both immediate and sustained reductions across multiple temperature intolerance-related quality of life domains, highlighting the efficacy of this technology in improving POTS symptoms." Solidifying its technological moat, Embr Labs was awarded two foundational patents in Japan for the Embr Wave 2. The first protects the proprietary delivery of physiologically optimized thermal waves, allowing users to personalize intensity and frequency for maximum therapeutic benefit. Japanese Patent No. 7805341 secures the device's innovative "Track and Learn" capability, generating customized usage logs to help users decode their thermal patterns. Both innovations are critical differentiators in digital thermal health. To accelerate the development of new thermal innovations, Embr Labs released a public open-source API and SDK, expanding the Embr Wave 2 into a thermal research platform for the global scientific community (link). Researchers can now leverage programmatic control to deliver precisely timed thermal stimuli from integrated research systems, using off-the-shelf software or developing their own. "We receive regular requests from researchers worldwide to incorporate Embr Wave 2 into their studies," said Matt Smith, Co-Founder and CTO of Embr Labs. "We are thrilled to support the continued understanding of the role thermal sensations play in improving the human experience." About Embr Labs Embr Labs is the leading healthtech company addressing health conditions through temperature. The company's technology delivers natural solutions to manage hot flashes, sleep issues, stress, and thermal discomfort. The company was founded at MIT and has won numerous awards, including the AARP Innovation in Aging Award, Time Magazine's Best Inventions, the iF Design Award and the FemtechWorld Award for Innovation in Menopause. CONTACT: Matt Smith: [email protected] SOURCE Embr Labs 21% more press release views with Request a Demo